Prolactinoma
18
5
6
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
5.6%
1 terminated out of 18 trials
83.3%
-3.2% vs benchmark
17%
3 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (18)
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
The PROMISE Survey
Validation of a Quality of Life Metric "Prolac-10"
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
Exercise Capacity and Physical Activity Level in Prolactinoma Patients
PRolaCT - Three Prolactinoma RCTs
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
Seoul National University Pituitary Disease Cohort Study
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
Rhinological Outcomes in Endonasal Pituitary Surgery
Study on Therapy of Non-invasive Prolactinoma
Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
Insulin Resistance in Women With Prolactinoma